Application Progress of 68Ga-PSMA PET/CT in Recurrent Prostate Cancer
The morbidity of prostate cancer (PCa) is high. Early diagnosis of recurrence after primary treatment is very important for the prognosis. Prostate specific membrane antigen (PSMA) is a transmembrane glycoprotein, with high expression in PCa. Small molecule inhibitors of the PSMA is labeled by 68Ga(...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | zho |
| Published: |
Magazine House of Cancer Research on Prevention and Treatment
2018-07-01
|
| Series: | Zhongliu Fangzhi Yanjiu |
| Subjects: | |
| Online Access: | http://html.rhhz.net/ZLFZYJ/html/8578.2018.17.1689.htm |
| Summary: | The morbidity of prostate cancer (PCa) is high. Early diagnosis of recurrence after primary treatment is very important for the prognosis. Prostate specific membrane antigen (PSMA) is a transmembrane glycoprotein, with high expression in PCa. Small molecule inhibitors of the PSMA is labeled by 68Ga(68Ga-PSMA). 68Ga-PSMA is used as imaging agent for PET/CT imaging. 68Ga-PSMA PET/CT can display the distribution of prostate cancer in vivo. Many European and American countries have used 68Ga-PSMA PET/CT to find recurrent lesions in prostate cancer patients and achieved good results. This technology is still in its initial stage in China. This article reviews the research progress of 68Ga-PSMA PET/CT in prostate cancer recurrence, in order to improve the understanding of this new technology in China. |
|---|---|
| ISSN: | 1000-8578 1000-8578 |